Navigation Links
Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
Date:10/7/2009

elected to the National Academy of Sciences in 1990. In 2001, Dr. Steitz together with Drs. Moore and Noller received the Rosenstiel Award for Distinguished Work in Basic Medical Sciences for their research on the ribosome. Currently, Dr. Steitz is the Sterling Professor of Molecular Biophysics and Biochemistry and a Howard Hughes Medical Institute Investigator at Yale University. His research in the field of protein and nucleic acid X-ray crystallography, including his recent work with Dr. Moore on the 50S ribosome structure has had wide-ranging impact in the global scientific community.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics, including radezolid, that can be used for the treatment of either community- or hospital-acquired infections. Delafloxacin (RX-3341) is a Phase 3-ready broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including methicillin-resistant S. aureus. Radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X as an oral/IV agent for treatment of serious Gram-positive infections, has completed two Phase 2 trials. The Rx-04 discovery progra
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
2. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
3. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
4. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015 "Whether it,s our family, our friends, ... In a single sentence, Dr. Anthony Coyle ... Pfizer,s Centers for Therapeutic Innovation (CTI), sums ... at America,s biopharmaceutical companies. CTI,s unique ... patient foundations and the National Institutes of Health (NIH) ...
(Date:3/26/2015)... 2015 Cardiologists at Beaumont Hospital, ... commercial implant of a device recently approved by the ... fibrillation. The Watchman Left Atrial Appendage Closure implant is ... to reduce the risk of stroke. Atrial ... more than 5 million Americans. Twenty percent of all ...
(Date:3/26/2015)... , March 26, 2015 When ... by their existing PACS vendor their system would ... determined that they needed a better structured solution ... selected Avreo interWORKS due to its interface capabilities ... meaningful use standards through to the hospital,s radiology ...
Breaking Medicine Technology:Collaboration for Cures: Teaming Up to Advance Science and Save Lives 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 2Beaumont Hospital, Royal Oak among first to offer alternative to blood-thinning medications for atrial fibrillation 3Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
... at Food and Drug Administration Meeting , ... WASHINGTON , July 20 ... and treating disease, representatives of the College of American Pathologists (CAP) ... increased oversight of laboratory developed tests (LDTs) and "direct-to-consumer" tests. Most ...
... SHENZHEN, China , July 20 /PRNewswire-Asia-FirstCall/ -- China Nepstar,Chain ... largest,drugstore chain in China based on the number of directly ... card. , , , ... Beginning in May 2010 , Nepstar started to expand its ...
Cached Medicine Technology:CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 2CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 3CAP Leaders Stress Need for Oversight of Direct-to-Consumer and Laboratory Developed Tests 4China Nepstar Chain Drugstore Provides Updates on Shopper's Card Program 2China Nepstar Chain Drugstore Provides Updates on Shopper's Card Program 3China Nepstar Chain Drugstore Provides Updates on Shopper's Card Program 4
(Date:3/28/2015)... (PRWEB) March 28, 2015 Lately the ... media regarding recent changes and proposals around the NCAA. ... current and former collegiate student-athletes across a spectrum of ... reflect on common challenges. The special panel consists of ... in sports ranging from football, track and field, baseball, ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness ... Chesapeake Conference Center in Chesapeake, Virginia. Each year, ARDX ... women in the Hampton Roads region. The 2015 Women’s ... Women grow stronger through sharing their stories and learning ... the WWC™ theme is T-talk where we will share a ...
(Date:3/27/2015)... 27, 2015 Wellness for Cancer–the first ... criteria for the spa and wellness industry–has certified Hands ... have experienced or are living with cancer. Hands ... 365® Network, will be identified with a special Wellness ... provider of safe, therapeutic services for cancer patients. , ...
(Date:3/27/2015)... City, Mo (PRWEB) March 27, 2015 ... complications for patients undergoing percutaneous coronary intervention (PCI), ... studies have observed a “risk-treatment paradox,” in which ... gain from treatment are treated less often with ... Researchers at Saint Luke’s Mid America Heart Institute ...
(Date:3/27/2015)... 27, 2015 The report “CountryFocus ... an essential source of information on and analysis ... Germany. Germany’s increasingly elderly population and its associated ... market. In 2013, the elderly accounted for 27.1% ... Compound Annual Growth Rate (CAGR) of 1.2% to ...
Breaking Medicine News(10 mins):Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4
... issue of the Journal of Periodontology (JOP) found that smokers ... than non-smokers. , The study followed 10 smokers and 10 ... smoke on the long term outcomes of a treatment to ... teeth. After two years, residual gum recession around the ...
... in APO gene not warranted, researchers say , , TUESDAY, Sept. ... are not as important an indicator of coronary risk as ... previously published studies. , The APO gene comes in three ... gene produce a protein that is an important component of ...
... Sept. 18 Eli Lilly and Company,(NYSE: ... M.D., Ph.D., F.R.C.P.,will join Lilly in January, 2008, ... division responsible for development of Lilly,s,expanding diabetes and ... Tan, Distinguished Medical Fellow, Diabetes and Endocrine, who ...
... 18 Christina Economos, PhD,principal investigator of Shape Up ... to curb childhood obesity, will present,her research at the ... 31st in Boston. "Shape Up Somerville" was a ... third graders in the culturally diverse Boston,suburb of Somerville, ...
... Quality Forum (NQF) and The Joint Commission today announced the,2007 ... Quality,Awards. Honorees were selected in all four award categories., ... ACHIEVEMENT (2 RECIPIENTS), -- Flaura Koplin Winston, M.D., Ph.D. ... Prevention at The Children,s Hospital of Philadelphia and the ...
... today that it has received an award of more ... the Johns Hopkins Institute for Clinical and Translational Research ... Hopkins researchers to hasten and improve the process of ... and eventually to the community. , This grant ...
Cached Medicine News:Health News:Study Downgrades Gene as Heart Risk Factor 2Health News:Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division 2Health News:Success of 'Shape-Up Somerville' Childhood Obesity Intervention to be Presented at the Friedman School Symposium at Tufts, October 29-31, 2007 - Boston 2Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 2Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 3Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 4Health News:2007 John M. Eisenberg Patient Safety and Quality Award Recipients Announced 5Health News:Johns Hopkins receives $100 million grant to speed research from clinic to community 2
... Reposable system components for creating each access port are ... is packaged sterile together with either a 5 mm ... needle is packaged non-sterile; 5 mm, 7/8 mm, ... 5 mm, 7/8 mm, 10 mm and 12 ...
VERSAPORT™ Plus RT Single Use Obturators for use with VERSAPORT™ RT Reusable Cannulae....
The SURGINEEDLE™ is a veress type needle that is used to insufflate the abdomen to create pneumoperitoneum....
... complete line of Surgical Access ...unlike any ... OnePort™ trocar system is actually four systems ... operationally flexible and clinically adaptive to all ... in disposability and bladed or dilating tip ...
Medicine Products: